Sutro Biopharma

#7409

Rank

$409.37M

Marketcap

United States

Country

Leadership team

Mr. William J. Newell J.D. (CEO & Director)

Mr. Edward C. Albini (CFO & Sec.)

Dr. Trevor J. Hallam (Pres of Research & Chief Scientific Officer)

Products/ Services

Biotechnology, Information Technology, Medical

Number of Employees

100 - 500

Headquarters

South San Francisco, California, United States

Established

2003

Company Registration

SEC CIK number: 0001382101

Revenue

20M - 100M

Traded as

STRO

Social Media

URL

https://www.sutrobio.com

Overview

Location

Recognition and Award

References

Summary

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

History

Sutro Biopharma was founded in 2003 as a biopharmaceutical drug discovery and development company focused on the development of targeted biologics. In 2012, Sutro expanded its drug discovery and development capabilities with the acquisition of Liberty Diagnostics, a technology-enabled drug development platform, and over the next two years leveraged that technology to develop several novel targeted biologics candidates. In 2017, Sutro successfully completed the first human Phase 1 clinical trial for its lead candidate, and in 2018 was awarded $107 million in Series B funding to advance its platform of targeted biologic therapeutics.

Mission

At Sutro Biopharma, our mission is to use cutting-edge biotechnologies to discover, develop and manufacture transformative medicines that have the potential to significantly improve the lives of patients and their families.

Vision

Our vision is to be a leader in the development and delivery of targeted protein therapeutics for significant unmet medical needs.

Key Team

Ms. Jane Chung R.Ph. (Chief Commercial Officer)

Ms. Linda A. Fitzpatrick (Chief People & Communications Officer)

Mr. David Pauling J.D., M.A. (Gen. Counsel)

Dr. James R. Swartz Ph.D., Sc.D. (Founder)

Dr. Nicki Vasquez Ph.D. (Chief Portfolio Strategy & Alliance Officer)

Dr. Shabbir T. Anik (Chief Technical Operations Officer)

Ms. Annie J. Chang M.B.A. (VP of Investor Relations)

Recognition and Awards

Sutro Biopharma has been featured in numerous publications and lists, including the prestigious FierceBiotech 25, Fortune's 2019 Change the World list, and MIT Technology Review's 100 Most Influential Companies.